Pharmacokinetics of Indinavir Combined with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Children
So far, no pediatric doses for indinavir combined with ritonavir have been defined. This study evaluated the pharmacokinetics of 400 mg of indinavir/m 2 combined with 125 mg of ritonavir/m2 every 12 h (q12h) in 14 human immunodeficiency virus type 1-infected children. The area under the concentration-time curve from 0 to 24 h and the minimum concentration of drug in serum for indinavir were similar to those for 800 mg of indinavir-100 mg of ritonavir q12h in adults, while the maximum concentration of drug in serum was slightly decreased, with geometric mean ratios (90% confidence intervals in parentheses) of 1.1 (0.87 to 1.3), 0.96 (0.60 to 1.5), and 0.80 (0.68 to 0.94), respectively.
|Persistent URL||dx.doi.org/10.1128/AAC.48.5.1904-1907.2004, hdl.handle.net/1765/54835|
|Journal||Antimicrobial Agents and Chemotherapy|
Bergshoeff, A.S, Fraaij, P.L.A, van Rossum, A.M.C, Verweel, G, Wynne, L.H, Winchell, R.J, … Burger, D.M. (2004). Pharmacokinetics of Indinavir Combined with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Children. Antimicrobial Agents and Chemotherapy, 48(5), 1904–1907. doi:10.1128/AAC.48.5.1904-1907.2004